FDA Clocks Review Time for LOQTORZI Patent Boost
Published Date: 5/30/2025
Notice
Summary
The FDA has set the official review period for LOQTORZI, a new medicine, so its patent can be extended. This helps the company behind LOQTORZI get extra time to protect their invention before others can copy it. This means the drug maker could have more exclusive sales time, which might impact when generic versions can appear.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Patent Extension May Delay Generics
The FDA set the official regulatory review period for LOQTORZI so the drugmaker can apply to extend a patent on this human biological product. That extension could give the company extra exclusive sales time for LOQTORZI and might delay when generic or biosimilar versions can appear. If you buy or pay for LOQTORZI, that could mean waiting longer for cheaper alternatives.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in